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Abstract: Levetiracetam is a second-generation antiepileptic drug (AED) with a unique 
chemical structure and mechanism of action. The extended release formulation of levetiracetam 
(Keppra XR™; UCB Pharma) was recently approved by the Food and Drug Administration for 
adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and 
older with epilepsy. This approval is based on a double-blind, randomized, placebo-controlled, 
multicenter, multinational trial. Levetiracetam XR allows for once-daily dosing, which may 
increase compliance and, given the relatively constant plasma concentrations, may minimize 
concentration-related adverse effects. Levetiracetam’s mode of action is not fully elucidated, but 
it has been found to target high-voltage, N-type calcium channels as well as the synaptic vesicle 
protein 2A (SV2A). Levetiracetam has nearly ideal pharmacokinetics. It is rapidly and almost 
completely absorbed after oral ingestion, is 10% protein-bound, demonstrates linear kinetics, 
is minimally metabolized through a pathway independent of the cytochrome P450 system, has 
no significant drug–drug interactions, and has a wide therapeutic index. The most common 
reported adverse events with levetiracetam XR were somnolence, irritability, dizziness, nausea, 
influenza, and nasopharyngitis. Levetiracetam XR provides an efficacious and well-tolerated 
treatment option for adjunctive therapy in the treatment of partial-onset seizures.
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Introduction
Extended release levetiracetam (Keppra XR™; UCB Pharma) is a relatively new 
antiepileptic drug (AED) with a unique chemical structure and mechanism of action. 
Its use is indicated by the Food and Drug Administration (FDA) for adjunctive therapy 
in the treatment of partial-onset seizures in patients 16 years of age and older. This 
approval is based on a recent double-blind, randomized, placebo-controlled, multicenter, 
multinational trial that included 158 patients between the ages of 12 and 70.1
Levetiracetam was originally approved by the US FDA and the European Medicines 
Evaluation Agency in 1999 as adjunctive treatment for partial-onset seizures in adults. 
This approval was based on the results of 3 double-blind, randomized, multicenter 
trials including a total of 904 patients.2–4
Levetiracetam XR was developed to provide patients with the convenience of 
once-daily dosing, which may improve drug compliance and tolerability.1,5
Mechanism of action
While much progress has been made to elucidate the mode of action of levetiracetam, 
its precise mechanism of action is still not fully understood. The mechanism of action Neuropsychiatric Disease and Treatment 2009:5 468
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of levetiracetam is distinct from first-generation and other 
second-generation AEDs. Levetiracetam does not share a high 
affinity for many known targets for existing AEDs including 
phenytoin, carbamazepine, sodium valproate, phenobarbital, 
dimethadione or benzodiazepines.6 In addition, levetiracetam 
appears not to work by the three classic routes of other AEDs: 
sodium channel modulation, low-voltage-activated (T-type) 
calcium channel modulation, and direct gamma-aminobutyric 
acid (GABA) facilitation.
Animal models
Levetiracetam is devoid of anticonvulsant activity in the 
two classic acute seizure models used for AED screening, 
including the maximal electric shock seizure test and the 
pentylenetetrazol seizure test. However, it does dem-
onstrate anticonvulsive effects in the acute corneal 
electroshock model and the selective chemoconvulsant 
seizure models, including pilocarpine and kainic acid 
induced models.7
Kindling, the phenomenon of repeated application of 
an initially subconvulsive stimulus leading to develop-
ment of spontaneous seizures of increasing severity and 
duration, is a reliable way to examine the anticonvulsive and 
antiepileptogenic properties of AEDs.8 The rate of kindling 
progression is used as a marker of antiepileptogenic potency. 
Levetiracetam exerts a significant antiepileptic effect, even 
after discontinuation of therapy, in kindled models and in 
the double mutant (tm/tm, zi/zi) spontaneously epileptic rat 
(SER) model, which exhibits both tonic and absence-like 
seizures.7,9–11
ion channels
Levetiracetam has no inhibitory effect on sodium or 
low-voltage-activated, T-type calcium channels in rat neocor-
tical neurons12 and does not have a high affinity for GABA, 
N-methyl d-aspartate (NMDA) or glutamate receptors.6,7,11 
Levetiracetam reduces high-voltage, N-type, calcium chan-
nel currents in isolated rat CA1 hippocampal neurons but 
does not have an effect on L-type, P-type or Q-type calcium 
channels.13,14 This effect occurs within a few seconds and 
suggests a direct interaction of levetiracetam with the N-type 
channel, rather than a second messenger pathway.
Levetiracetam has also been shown to reduce caffeine 
induced calcium currents in rat hippocampal cell cultures,15 
which may facilitate GABA transmission indirectly.16,17 
In addition, levetiracetam has been demonstrated to antago-
nize neuronal hypersynchronization in rat hippocampal slices 
in high-potassium, low-calcium bathing fluid.18
Synaptic vesicle protein 2A
Early work by Noyer et al suggested a protein-binding site 
that was highly specific to central nervous system (CNS) 
synaptic plasma membranes.6 More recently, that site was 
identified by Lynch et al as the synaptic vesicle protein 2A 
(SV2A), a plasma membrane protein of approximately 
90 kDa that is nearly ubiquitous throughout the CNS.19 Leve-
tiracetam binds reversibly, saturably, and stereo-specifically 
to this receptor site.6,15,19,20
The exact role of the SV2A protein is not fully understood; 
it is thought to participate in the physiologic functioning of the 
synaptic vesicle.19 Its role in epilepsy is supported by the fact 
that SV2A knock-out mice develop seizures soon after birth 
and usually die within 3 weeks.21 Furthermore, the affinity 
of various compounds to the SV2A binding site correlates 
strongly with their anti-seizure potency in the audiogenic 
epilepsy mouse model.19
Pharmacokinetic profile
Physical and chemical properties
Keppra XR tablets are film-coated extended release tablets 
that contain 500 mg of levetiracetam, a structurally unique 
AED. Levetiracetam is the S-enantiomer of α-ethyl-2-oxo-
1-pyrrolidine acetamide. Its molecular formula is C8H14N2O2, 
and its molecular weight is 170.21. Levetiracetam is a white 
to off-white crystalline powder that has a faint odor and bitter 
taste.22 It is essentially water soluble.
Absorption and distribution
Levetiracetam is almost completely absorbed after oral 
administration, exhibits 95% bioavailability, has a volume 
of distribution of 0.5 to 0.7 L/kg (close to that of intracel-
lular and extracellular water), and in rats has been shown to 
rapidly penetrate the brain without brain region specificity. 
In addition, levetiracetam is not significantly protein bound 
(10%).22,23
In a recent study by Rouits et al 1000 mg of levetiracetam 
XR (two 500 mg XR tablets) was found to be bioequivalent 
to two 500 mg immediate release (IR) tablets given 12 hours 
apart, with comparable maximal plasma concentrations (Cmax) 
and area under the plasma concentration vs time (AUC). 
Under fasting conditions, the median time to maximal 
plasma concentration (Tmax) was 4 hours for levetiracetam XR 
vs 0.9 hours for levetiracetam IR (Table 1). Time to peak was 
further prolonged by 2.5 hours when the XR tablet was given 
after intake of a high-fat, high-calorie breakfast. However, 
the AUC and Cmax were similar to those in the fasting state. 
Furthermore, based on the slopes of the regression vs dose, Neuropsychiatric Disease and Treatment 2009:5 469
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the Cmax and AUC were dose proportional after a single 
dose of 1000 mg, 2000 mg, and 3000 mg levetiracetam XR. 
The half-life, apparent clearance, and apparent volume of 
distribution were dose-independent. Therefore, this study 
concluded that: (1) levetiracetam XR 1000 mg once a day 
is bioequivalent to levetiracetam IR 500 mg bid; (2) there is 
no food effect; and (3) the absorption of levetiracetam XR 
is dose proportional from 1000 mg to 3000 mg.5
Metabolism and elimination
The metabolism of levetiracetam is independent of the 
hepatic cytochrome P450 system. Sixty-six percent of an 
administered dose of levetiracetam is excreted unchanged 
in the urine, and 27% is excreted as inactive metabolites.24 
The major metabolic pathway involves enzymatic hydrolysis 
of the acetamide group, which results in one major inactive 
carboxylic acid metabolite (L057).23
Levetiracetam is rapidly cleared, with about 93% of a given 
dose excreted within 48 hours of oral administration. The rate 
of renal clearance is 0.6 mL/min/kg. Levetiracetam’s plasma 
half-life in healthy subjects is approximately 6 to 8 hours.23 
Half-life and apparent clearance of both levetiracetam IR 
and XR are dose-independent.5 The mechanism of excretion 
is through glomerular filtration, followed by partial tubular 
reabsorption. The major metabolite, L057, is excreted by 
glomerular filtration and active tubular secretion with a renal 
clearance of 4 mL/min/kg.23
The rate of elimination of levetiracetam is dependent on 
creatinine clearance; therefore, dose adjustments are required 
in patients with renal impairment (Table 2).22 The plasma 
elimination half-life of levetiracetam IR in elderly subjects 
increases to between 10 and 11 hours.24 This is likely due to 
an age-related decrease in creatinine clearance, which may 
require a decrease in daily dose.
The pharmacokinetics of levetiracetam IR were studied 
in 16 patients with varying degrees of liver cirrhosis.25 
Patients with mild to moderate hepatic dysfunction require no 
adjustment of levetiracetam dose. However, those with severe 
cirrhosis and concomitant renal insufficiency (hepato-renal 
syndrome) may require a lower levetiracetam dose.
Pharmacokinetics in pediatric patients
The pharmacokinetic profile of levetiracetam XR has not been 
studied in patients below the age of 16. However, the pharma-
cokinetics of a single 20 mg/kg dose of levetiracetam IR in 12 
children aged 2 to 46 months was studied.26 The mean half-life 
was 5.3 ± 1.3 hours. This is slightly shorter than in children 
aged 6 to 12 years, previously reported at 6 ± 1.1 hours.27 In 
addition, the apparent clearance (1.46 ± 0.42 mL/min/kg) 
was more rapid than that seen in adults.
Pharmacokinetic interactions
Levetiracetam has no known clinically significant drug 
interactions. In vitro studies have demonstrated that neither 
levetiracetam nor its major metabolite have an effect on 
various cytochrome P450 isoenzymes.23 Several studies 
in healthy subjects have demonstrated no pharmacoki-
netic interaction between levetiracetam and phenytoin,28 
warfarin,29 digoxin,30 and an oral contraceptive containing 
ethinyl estradiol and levonorgestrel.31 In addition, a pooled 
analysis of data from several randomized clinical trials 
showed that adjunctive therapy with levetiracetam did 
not influence the steady-state concentrations of concomi-
tantly administered carbamazepine, phenytoin, valproate, 
lamotrigine, gabapentin, phenobarbital or primidone.32
An earlier pooled analysis investigated the effects of vari-
ous AEDs on the pharmacokinetics of levetiracetam.33 This 
study showed that, although there was a trend towards lower 
serum levetiracetam levels and a shorter half-life in patients 
on concomitant enzyme-inducing AEDs, the estimated 
half-life of levetiracetam in these patients was still within 
the expected 6- to 8-hour range for healthy subjects and the 
differences in pharmacokinetic parameters were considered 
unlikely to be clinically significant.
Clinical efficacy
Pivotal trial for extended release 
levetiracetam
In a recent double-blind, randomized, placebo-controlled, mul-
ticenter, multinational trial of levetiracetam XR as adjunctive 
treatment of partial-onset seizures with or without secondary 
generalization in adults with epilepsy, the drug’s efficacy 
Table 1 Bioequivalence of levetiracetam ir and xr under fasting 
conditions
Parameter Levetiracetam 
IR 500 mg q12 h
Levetiracetam 
XR 1000 mg
Cmax (µg/mL) 19.7 17.4
Tmax (h) 0.9 4
AUC(0–t) (µg/mL) 317 307
AUC∞ ((µg/mL) 325 313
Notes: AUC(0–t): area under the plasma-concentration–time curve from time 0 to 
last measurable time point.
AUC∞: area under the plasma-concentration–time curve extrapolated from time 0 to 
infinity.
Adapted with permission from rouits e, Burton i, Guénolé e, Troenaru MM, 
Stockis A, Sargentini-Maier ML. Pharmacokinetics of levetiracetam xr 500 mg 
tablets. Epilepsy Res. 2009;84(2–3):224–231.5 Copyright © 2009 elsevier.Neuropsychiatric Disease and Treatment 2009:5 470
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and tolerability were demonstrated.1 One hundred fifty-eight 
patients (intention-to-treat population) between 12 and 70 years 
of age with a diagnosis of partial-onset seizures refractory to 
1 to 3 AEDs were randomized to levetiracetam XR (n = 79) 
or placebo (n = 79). The most frequently used concomitant 
AEDs were carbamazepine (53%), valproate (37%), topiramate 
(20%), lamotrigine (19%), phenytoin (13%), clobazam (10%) 
and phenobarbital (9.5%). The trial began with an 8-week 
baseline period in which eligibility was determined. Thereaf-
ter, patients were randomized to receive either levetiracetam 
XR 1000 mg daily or placebo during the 12-week treatment 
period. There was no uptitration period. The primary efficacy 
variable was based on the frequency of partial-onset seizures 
per week over the 12-week treatment period.
The median percent reduction in seizure frequency per 
week from baseline was 46% in the levetiracetam XR group 
and 33.4% in the placebo group. The estimated median 
percent reduction in seizures per week from baseline of 
levetiracetam XR over placebo was 14.4% (two-sided 95% CI 
0.9%–26.0%; P = 0.038) in the intention-to-treat population. 
The responder rate (50% reduction in seizure frequency per 
week from baseline) was 43% in the levetiracetam XR group 
and 29% in the placebo group. In addition, during the entire 
12-week treatment period, 8/79 (10.1%) of patients treated 
with levetiracetam XR were seizure-free in comparison to 
1/79 (1.3%) of placebo-treated patients.
Pivotal trials for immediate release 
levetiracetam
The initial approval of levetiracetam for the adjunctive 
treatment of partial-onset seizures in adults is based on the 
results of 3 double-blind, randomized, placebo-controlled, 
multicenter trials.2–4 The American trial by Cereghino et al 
looked at the efficacy and tolerability of 500 mg bid and 
1500 mg bid of levetiracetam as add-on therapy in patients 
16 to 70 years of age with partial-onset seizures refrac-
tory to at least 2 AEDs.3 The study consisted of a 12-week 
placebo baseline period, a 4-week drug uptitration period, 
and a 14-week treatment/evaluation period. Two hundred 
ninety-four patients were randomized: 98 to levetiracetam 
1000 mg/day, 101 to levetiracetam 3000 mg/day and 95 to 
placebo. The median percent reduction in seizure frequency 
from baseline was 32.5% with levetiracetam 1000 mg/day, 
37.1% with levetiracetam 3000 mg/day, and 6.8% with 
placebo (P  0.001). The median percent reduction in sei-
zure frequency over placebo was 20.9% with levetiracetam 
1000 mg/day (P  0.001) and 27.7% with levetiracetam 
3000 mg/day (P  0.001). The responder rate was 33% 
with levetiracetam 1000 mg/day, 39.8% with levetiracetam 
3000 mg/day, and 10.8% with placebo (P  0.001). Eight 
patients in the levetiracetam 3000 mg/day group were 
seizure-free during the entire 14-week evaluation period 
compared to none in the placebo group (P = 0.01).
In one European trial by Shorvon et al, the efficacy and 
tolerability of 500 mg bid and 1000 mg bid of levetiracetam 
as add-on therapy in patients 16 to 65 years of age with 
partial-onset seizures refractory to 1 to 2 AEDs was assessed.4 
The study consisted of an 8-week baseline period, a 4-week 
uptitration period, and a 12-week treatment/evaluation 
period. Three hundred twenty-four patients were randomized: 
112 in the placebo group, 106 in the levetiracetam 1000 mg/day 
group, and 106 in the levetiracetam 2000 mg/day group. 
The median percent reduction in weekly seizure frequency 
from baseline was 17.7% with levetiracetam 1000 mg/day 
(P  0.001), 26.5% with levetiracetam 2000 mg/day 
(P  0.001), and 6.1% with placebo. The median percent 
reduction in seizure frequency over placebo was 16.4% 
with levetiracetam 1000 mg/day (P = 0.006) and 17.7% 
with levetiracetam 2000 mg/day (P = 0.003). The responder 
rate was 22.8% with levetiracetam 1000 mg/day (P  0.02), 
31.6% with levetiracetam 2000 mg/day (P  0.001), and 
10.4% with placebo.
In another European trial by Ben-Menachem and Falter, 
the efficacy and tolerability of levetiracetam 3000 mg/day 
as add-on therapy in patients 16 to 70 years of age with 
partial-onset seizures was assessed.2 The study consisted 
of a 12-week baseline period, a 4-week up-titration period, 
a 14-week add-on evaluation period, and a monotherapy 
phase (for those who responded well to levetiracetam or 
placebo) that included a maximum of 12 weeks of down-
titration of concomitant AED and 12 weeks of monotherapy 
with levetiracetam 3000 mg/day. The primary efficacy 
variable was the percentage of patients who completed the 
monotherapy phase. Two hundred eighty-six patients were 
randomized: 181 to levetiracetam 3000 mg/day and 105 
to placebo. Of this intention-to-treat population, 19.9% of 
Table 2 recommended dosing adjustment in adults with impaired 
renal function22
Degree of renal 
impairment
Creatinine clearance 
(mL/min/1.73 m2)
Dose per day
Normal 80 1000 to 3000 mg
Mild 50 to 80 1000 to 2000 mg
Moderate 30 to 50 500 to 1500 mg
Severe 30 500 to 1000 mgNeuropsychiatric Disease and Treatment 2009:5 471
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patients in the levetiracetam group completed the study 
in comparison to 9.5% in the placebo group (P = 0.029). 
In reference to the add-on phase, the median percent reduc-
tion in seizure frequency from baseline was 39.9% with leve-
tiracetam and 7.2% with placebo (P  0.001). The responder 
rate was 42.1% with levetiracetam and 16.7% with placebo 
(P  0.001). Fourteen patients in the levetiracetam group 
(8.2%) remained seizure-free during the add-on evaluation 
period vs one in the placebo group (P = 0.012). The results 
of the monotherapy phase are discussed below.
Pivotal trial of immediate release 
levetiracetam in children
The efficacy of levetiracetam XR has not been studied in 
children. However, levetiracetam IR is FDA approved for 
the adjunctive treatment of refractory partial-onset seizures in 
children above the age of 4 based on a double-blind, placebo-
controlled, multicenter trial involving an intention-to-treat 
population of 198 patients 4 to 16 years of age that demon-
strated a 26.8% reduction in weekly seizure frequency from 
baseline in patients taking 60 mg/kg/day of levetiracetam vs 
placebo.34 The pattern and incidence of treatment-emergent 
adverse events were similar in the levetiracetam and placebo 
groups. Several smaller studies have supported the efficacy 
and safety of add-on levetiracetam in children with refractory 
partial-onset seizures.35–38
idiopathic generalized epilepsies
Levetiracetam also appears to be effective in the treatment 
of idiopathic generalized epilepsies. One recent randomized, 
double-blind, placebo-controlled, multicenter trial of 
adjunctive treatment with levetiracetam IR 3000 mg/day 
in 120 patients 12 years of age with myoclonic seizures 
associated with idiopathic generalized epilepsies showed 
a reduction of 50% in the number of days/week with 
myoclonic seizures in 58.3% of patients in the levetiracetam 
group and in 23.3% of patients in the placebo group 
(P  0.001). Freedom from myoclonic seizures was seen 
in 25% of patients in the levetiracetam group and 5% of 
patients in the placebo group (P = 0.004). Freedom from 
all seizure types occurred in 21.7% of levetiracetam-
treated patients and in 1.7% of placebo-treated patients 
(P  0.001).39
Another randomized, double-blind, placebo-controlled, 
multicenter, parallel-group study evaluated the efficacy and 
tolerability of adjunctive levetiracetam in 164 patients 4 to 
65 years of age with uncontrolled generalized tonic-clonic 
(GTC) seizures associated with idiopathic generalized 
epilepsies. The mean reduction in GTC seizure frequency 
per week was 56.5% in the levetiracetam group and 28.2% 
in the placebo group (P = 0.004). The responder rate was 
72.2% for the levetiracetam group and 45.2% for the placebo 
group (P  0.001). The percent of patients free of all seizures 
was 24.1% for levetiracetam-treated patients and 8.3% for 
placebo-treated patients (P = 0.009).40
Monotherapy and newly diagnosed 
epilepsy
Levetiracetam XR has not been studied in monotherapy. 
As described earlier, one of the pivotal levetiracetam 
IR trials included a 12-week monotherapy phase with 
levetiracetam 3000 mg/day.2 Only patients who responded 
well to levetiracetam or placebo during the add-on phase 
were eligible to enter the monotherapy phase. Of the 
239 patients who completed the add-on phase, 86 were 
eligible to enter the monotherapy phase (placebo, n = 17; 
levetiracetam, n = 69). For ethical reasons, 8/17 placebo-
treated patients were switched to levetiracetam but remained 
in the placebo group for analyses. After meeting escape 
criteria, 25 patients were withdrawn during the downtitration 
period. Out of the 69 levetiracetam-treated patients, 49 were 
successfully downtitrated to monotherapy and 36 (19.9%) 
completed the study. Of the 17 placebo-treated patients, 
12 were successfully down-titrated to monotherapy and 
10 (9.5%) completed the study (4 of which had been 
switched to levetiracetam). The median percent reduction 
in seizure frequency from baseline during the monotherapy 
evaluation period was 73.8% (P = 0.037). The responder 
rate was 59.2%. Nine of the 49 patients taking levetiracetam 
were seizure-free. This study suggested that levetiracetam 
3000 mg/day may be effective as monotherapy in the 
treatment of patients with partial-onset seizures refractory 
to other AEDs; however, neither the FDA nor the American 
Academy of Neurology have endorsed this use due to the 
unusual trial design.41
A large multicenter, double-blind, noninferiority, 
parallel-group trial assessed the efficacy and tolerability 
of levetiracetam in comparison to controlled-release 
carbamazepine as first treatment in 579 patients with newly 
diagnosed epilepsy. This study found equivalent seizure 
freedom rates in both groups at 6 months (73% levetiracetam; 
72.8% controlled-release carbamazepine). There was a trend 
towards higher withdrawal rates due to adverse events in the 
carbamazepine group when compared to the levetiracetam 
group (19.2% vs 14.4%); however, this was not statistically 
significant.42 Moreover, several retrospective studies Neuropsychiatric Disease and Treatment 2009:5 472
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have suggested that levetiracetam is effective and safe as 
monotherapy in adults with epilepsy.43–46
Safety and tolerability
Adverse events in pivotal adult trials
In its pivotal trial, levetiracetam XR was generally well 
tolerated.1 Overall, the incidence of adverse events did 
not significantly differ between the placebo and treatment 
groups. Treatment-emergent adverse reactions that had a 
higher incidence with levetiracetam XR compared with 
placebo were somnolence, irritability, dizziness, nausea, 
influenza and nasopharyngitis (Table 3). Headache was 
reported more frequently in the placebo arm. Five patients in 
the levetiracetam group discontinued due to adverse events 
(mouth ulceration, skin rash, asthenia, seizures) that were 
considered by the investigators to be causally related to the 
medication. Two patients in the placebo arm discontinued 
treatment due to adverse events. There were no clinically 
relevant changes from baseline in vital signs, body weight, 
laboratory values, electrocardiograms or physical examina-
tion findings.1
Furthermore, in the original pivotal trials that led to FDA 
approval of levetiracetam, treatment-emergent adverse reac-
tions reported more often with levetiracetam IR than placebo 
were somnolence, asthenia, dizziness, headache, infection, 
rhinitis, and flu syndrome.47 Infections consisted mostly of 
common colds and upper respiratory infections that were not 
associated with elevated white blood cell counts.48 Of note, 
the IR trials used a different coding dictionary (COSTART) 
than the XR study (Med-DRA).
Long-term studies and tolerability
The pivotal trials for levetiracetam XR and IR are short-term 
studies of efficacy and tolerability that do not assess long-
term outcomes. Thus far, there are no studies investigating 
the long-term outcomes of patients treated with levetiracetam 
XR. There are several for the IR formulation.
In a 2-year study of 301 patients 1 to 75 years of age with 
refractory epilepsy on levetiracetam IR, 45.8% discontinued 
treatment during the 24 month follow-up period. Discontinu-
ation of levetiracetam was due to an adverse event in 6% and 
due to a combination of lack of efficacy and adverse events 
in 16.3%. The most frequently reported side effects at the 
time of discontinuation were tiredness (13.8%), agitation, 
aggression and hyperirritability (13.8%), depression and 
apathy (13.1%), and sleepiness (8.5%).49
In another large cohort of 811 patients with refractory 
epilepsy 14 to 79 years of age on levetiracetam IR, the 
3-year retention rate was 58%. Discontinuation was due to 
an adverse event in 10% and due to a combination of adverse 
events and lack of efficacy in 9%. The most frequent adverse 
events were somnolence, dizziness, headache, behavior 
problems, gastrointestinal disturbances and skin rash.50
Additionally, a follow-up study of 280 patients 17 to 
72 years of age with refractory partial-onset seizures that ben-
efited from levetiracetam IR during one of the original pivotal 
trials3 was performed. Eighty-one patients (28.9%) termi-
nated the study prematurely. Of these, 39 (13.9%) withdrew 
due to loss or lack of efficacy and 20 (7.1%) withdrew due 
to adverse events. This included 5 patients who died (deaths 
considered by investigator to be unrelated to treatment) and 
3 patients who withdrew due to a behavioral adverse event 
(aggression, irritability, intentional overdose).51
In a prospective analysis of 354 patients with refractory 
epilepsy on levetiracetam IR followed for 2 years, sedation 
was the most common side effect (10.7%). However, mood 
disturbance, which occurred in 17 patients (4.8%), was more 
likely to lead to discontinuation of treatment. This study also 
found that a slower titration regimen was associated with an 
increased rate of retention.52
Psychiatric and behavioral adverse events
Behavioral adverse events were noted in open-label 
studies and post-marketing analyses of levetiracetam IR. 
A systematic review of levetiracetam’s safety profile reported 
the incidence of behavioral problems (agitation, anti-social 
reaction, anxiety, apathy, depersonalization, depression, 
emotional lability, euphoria, hostility, nervousness, neurosis, 
and personality disorder) in placebo-controlled epilepsy 
trials at 13.5% in the levetiracetam IR group vs 6% in the 
placebo group.48 Behavioral adverse events did not appear to 
be dose-related, and there was no correlation to whether the 
patient was a treatment responder. Therefore, the theory of 
“forced normalization” appears not to apply. Further logistic 
regression analyses also revealed that patients with a previous 
Table 3 Adverse events reported by 5% of patients in the 
levetiracetam xr group1
Adverse event Levetiracetam XR  Placebo 
Somnolence 7.8% 2.5%
Influenza 7.8% 3.8%
irritability 6.5% 0
Nasopharyngitis 6.5% 5.1%
Nausea 5.2% 2.5%
Dizziness 5.2% 2.5%Neuropsychiatric Disease and Treatment 2009:5 473
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history of psychiatric disorders were more likely to report 
behavioral adverse events.47,48
In a study of 517 patients on levetiracetam IR, 10.1% 
developed a psychiatric adverse effect (3.5% aggressive 
behavior, 2.5% affective disorder, 2.3% emotional lability, 
1.2% psychosis, and 0.6% other behavioral abnormalities). 
A significant association was found in patients with a history 
of status epilepticus, febrile convulsions, or previous psy-
chiatric disorder. Concomitant use of lamotrigine appeared 
to have a protective effect.53
Interestingly, the incidence of affective symptoms is 
significantly higher among patients on levetiracetam for 
epilepsy than in those on it for cognition or anxiety, even 
when taken in similar doses. This raises the possibility that 
there is something inherently different in epilepsy patients 
that predisposes them to these behavioral side effects.54 Those 
with learning disabilities may also be at a higher risk. In a 
study of 184 adults with epilepsy on levetiracetam IR, 30% 
of which had a learning disability, there were significantly 
more behavioral adverse effects (23% vs 10%) in those with 
learning disabilities than those without.55
Tolerability in the elderly
The pivotal trial for levetiracetam XR did not contain a 
sufficient number of patients 65 years of age to reliably 
ascertain tolerability in this subgroup. However, conclusions 
can be drawn from trials involving the IR formulation.
In a subset analysis of the KEEPER trial, the efficacy and 
tolerability of levetiracetam as add-on therapy for partial-
onset seizures was evaluated in 78 patients 65 years of 
age. Somnolence was the most common reported adverse 
event, occurring in 16.7%. Dizziness occurred in 9%. 
Discontinuation of treatment due to an adverse event occurred 
in 19.2% of patients.56
Cramer et al compared treatment-emergent side effects in 
levetiracetam trials of young and elderly patients with anxiety 
and cognitive disorders and young patients with epilepsy. 
The only significant difference in reported adverse events 
between the young and elderly groups occurred in those with 
anxiety disorders, with headache and tremor occurring more 
frequently in the elderly patients. Overall, levetiracetam was 
well tolerated by all groups.57
Pregnancy and lactation
Levetiracetam XR falls under pregnancy category C, to be 
used only if the potential benefit justifies the potential risk 
to the fetus. Isoherranen et al used a well established mouse 
model of AED teratogenicity to study the developmental 
outcomes of fetuses exposed to levetiracetam or its major 
metabolite in humans, 2-pyrrolidone N-butyric acid 
(PBA). They found significantly reduced fetal weights 
in most groups and an increased incidence of skeletal 
abnormalities in both the PBA and levetiracetam groups. 
Two out of 107 fetuses exposed to 1200 mg/kg/day of leve-
tiracetam had cleft palate. Otherwise, no gross structural 
malformations among the exposed embryos were found, 
including those receiving a higher dose of levetiracetam 
(2000 mg/kg/day).58
In 2006, the UK Epilepsy and Pregnancy Register 
reported pregnancy outcomes in a cohort of women with 
epilepsy and first-trimester exposure to levetiracetam IR.59 
There were a total of 117 pregnancies, 39 of which were 
monotherapy exposures. Three of the 117 exposed preg-
nancies had a major congenital malformation. All of these 
occurred in pregnancies also exposed to other AEDs. The 
malformations included pyloric stenosis and spina bifida. 
Five minor congenital malformations occurred, also all in 
pregnancies exposed to polytherapy.
Additionally, in a study of 14 women with epilepsy on 
levetiracetam IR during pregnancy (8 on concomitant AEDs), 
breast milk levetiracetam concentrations and maternal, 
umbilical cord and infant levetiracetam plasma concen-
trations were studied.60 The mean milk: maternal plasma 
concentration of levetiracetam was 1.05, suggesting exten-
sive transfer into breast milk. Substantial placental transfer 
of levetiracetam was also found, and the estimated elimina-
tion half-life of levetiracetam in 13 neonates was 18 hours. 
However, the plasma concentrations in the infants were, on 
average, 13% that of maternal plasma concentrations. In light 
of the significant transfer of levetiracetam from mother to 
fetus and into breast milk, the low levetiracetam concentra-
tions in breast-fed neonates suggest rapid elimination of 
levetiracetam in neonates.
Discussion
Levetiracetam has many unique characteristics in regards 
to its mechanism of action: it lacks anticonvulsive activity 
in the maximal electric shock and the pentylenetetrazol 
seizure tests; it does not act at the three main sites of 
conventional AEDs; and it appears to offer disease-
modifying benefits in genetic and kindled epilepsy models. 
Thus far, only sodium valproate and, to a lesser extent, 
phenobarbital have demonstrated antiepileptogenic proper-
ties in the kindling model,61 but only do so at doses large 
enough to cause significant sedation and ataxia. Neither 
drug demonstrates antiepileptic properties in the genetic Neuropsychiatric Disease and Treatment 2009:5 474
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spontaneously epileptic rat (SER) model.11 All of these 
qualities distinguish levetiracetam from other first and 
second-generation AEDs.
Whether the antiepileptic properties of levetiracetam 
in kindled models translate to the clinical arena is uncer-
tain when consideration is given to the fact that clinical 
epilepsy, with the exception of a few rare syndromes, is not 
a progressive, self-perpetuating disorder.62 Levetiracetam 
has only demonstrated a delay in the development or an 
increase in the threshold required to acquire epilepsy in 
the models reviewed by this article, suggesting that it is 
a disease-modifying agent rather than being truly anti-
epileptogenic.63 Furthermore, the protection levetiracetam 
afforded in the genetic SER model may not hold up in 
clinical practice considering the rats have specific muta-
tions which have not been correlated in human causes of 
epilepsy and may make them metabolically and pharma-
cologically different.
Interestingly, levetiracetam appears to target sites 
previously not involved in anticonvulsive therapy, including 
high-voltage calcium channels and the SV2A receptor. These 
new mechanisms of action may contribute to levetiracetam’s 
low incidence of drug–drug interactions, making it especially 
useful in cases of refractory epilepsy in which polypharmacy 
often leads to increased adverse events.
An ideal antiepileptic drug is one that is efficacious in 
controlling seizures with no adverse events. The pharma-
cokinetic characteristics of this ideal AED would include: 
rapid absorption, good bioavailability, rapid achievement of 
steady-state concentrations, linear kinetics, minimal protein 
binding, absence of significant drug–drug interactions, a half-
life allowing daily or bid dosing, a wide therapeutic index, 
and no metabolism.24
Levetiracetam XR exhibits many of these ideal charac-
teristics. It is rapidly and almost completely absorbed after 
oral ingestion, is 10% protein-bound, demonstrates linear 
kinetics, is minimally metabolized via a pathway independent 
of the cytochrome P450 system, has no active metabolites, 
has no significant drug–drug interactions, allows for once-
daily dosing, and has a wide therapeutic index. Levetiracetam 
XR is ideal for patients with multiple medical problems on 
polytherapy and those with hepatic impairment. In addition, 
preliminary data suggest that levetiracetam is a good AED 
option for patients on chemotherapeutic agents.64,65 However, 
given that levetiracetam is renally excreted, dose adjustments 
are needed in patients with renal impairment and in some 
elderly patients due to an age-related decrease in creatinine 
clearance.
The efficacy, safety, and tolerability of levetiracetam 
for the adjunctive treatment of partial-onset seizures have 
been clearly proven. Additional studies have suggested 
efficacy of levetiracetam IR in the treatment of idiopathic 
generalized epilepsies and as monotherapy. Levetiracetam 
XR was well-tolerated in its pivotal trial. The most com-
mon adverse events reported were somnolence, irritability, 
dizziness, nausea, influenza, and nasopharyngitis. In addition, 
levetiracetam does not alter body weight,66 which may be 
a favorable characteristic. The most concerning associ-
ated adverse events are behavioral in nature and include 
agitation, anxiety, depression, nervousness, irritability and, 
rarely, psychosis. Those with learning disabilities and with a 
previous history of psychiatric illness may be at higher risk. 
Behavioral adverse events are reversible with discontinuation 
of levetiracetam.41
Data on pregnancy outcomes are limited; however, the UK 
Epilepsy and Pregnancy Register’s report on 117 pregnancies 
exposed to levetiracetam IR showed promising outcomes with 
only 3 major congenital malformations, all in polytherapy 
exposures. However, data on levetiracetam’s possible effect 
on cognitive development are lacking.
One of the possible benefits of levetiracetam XR is 
its once-daily dosing schedule because once and twice-
daily dosing have been shown to result in a higher rate of 
compliance, and there appears to be an inverse relation-
ship between the number of daily medication doses and 
compliance.67,68 Furthermore, because of relatively constant 
plasma concentrations, extended release formulations may 
minimize concentration-related adverse effects. These 
benefits should be weighed against the potential higher risk 
of a breakthrough seizure if a dose of a once-daily medi-
cation is missed, as the impact of a missed dose is greater 
the larger the dose and the less frequent the administration 
schedule.69
Conclusion
Extended release levetiracetam is a truly unique and valuable 
antiepileptic drug that can be added to the arsenal of existing 
treatment options for patients with epilepsy. Its favorable 
pharmacokinetic properties, lack of significant drug–drug 
interactions, overall safety and tolerability, and convenient 
once-daily dosing make levetiracetam XR an ideal add-on 
therapy for the treatment of partial-onset seizures. Future 
research will undoubtedly shed more light on the role of the 
SV2A receptor in the pathophysiology of epilepsy and pos-
sibly other hereto undiscovered biopharmacologic properties 
of levetiracetam.Neuropsychiatric Disease and Treatment 2009:5 475
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